famotidine has been researched along with Dyspepsia in 21 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Dyspepsia: Impaired digestion, especially after eating.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the present study, we aimed to investigate patients with a documented diagnosis of functional dyspepsia (FD) who had been admitted to our outpatient Gastroenterology Clinic and provided consent to participate in this randomized, double-blind, placebo-controlled trial of the therapeutic impact of famotidine on the symptoms and quality of life of FD patients." | 9.16 | Famotidine in the treatment of functional dyspepsia: a randomized double-blind, placebo-controlled trial. ( Amini, M; Babaei, M; Darvishi, A; Ghamar Chehreh, ME; Khedmat, H; Taheri, S; Valizadegan, G, 2012) |
| "Camostat mesilate is superior to famotidine for relieving epigastralgia in patients with functional dyspepsia." | 9.12 | Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective? ( Ashizawa, N; Hashimoto, T; Imaoka, T; Kinoshita, Y; Miyake, T; Shizuku, T, 2006) |
| "007), indigestion and reflux syndrome after famotidine treatment." | 9.11 | Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. ( Asaka, M; Kato, M; Kitamori, S; Konishi, S; Konno, J; Kudo, M; Meguro, T; Nakagawa, S; Shimizu, Y; Takeda, H; Watanabe, M, 2005) |
| "Sixty-four functional dyspepsia patients without Helicobacter pylori infection were randomly assigned to 15 mg/day of mosapride, 40 mg/day of famotidine, or 30 mg/day of tandospirone during an 8-week treatment." | 9.11 | Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. ( Chiba, T; Nakase, H; Seno, H, 2005) |
| "To determine the benefit of using an H2-receptor antagonist in children with abdominal pain and dyspepsia, 25 such children were enrolled in a double-blind, placebo-controlled trial of famotidine." | 9.09 | Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. ( Benkov, KJ; Birnbaum, AH; Goldenberg, MM; Schechter, CB; See, MC, 2001) |
| "In this multicenter prospective single-arm open-label study, 10,311 patients with a clinical diagnosis of chronic symptomatic gastritis were enrolled and each patient was administered famotidine at 20 mg/day for 4 weeks." | 7.78 | Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study. ( Chiba, T; Kinoshita, Y, 2012) |
| " Adverse events (AEs) were collected beginning at the first dose and continued through completion (54 weeks)." | 6.80 | One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| "In the pivotal efficacy and safety trials, discontinuation rates due to any cause and dyspepsia were significantly lower for the ibuprofen/famotidine combination versus ibuprofen alone." | 5.20 | One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| "In the present study, we aimed to investigate patients with a documented diagnosis of functional dyspepsia (FD) who had been admitted to our outpatient Gastroenterology Clinic and provided consent to participate in this randomized, double-blind, placebo-controlled trial of the therapeutic impact of famotidine on the symptoms and quality of life of FD patients." | 5.16 | Famotidine in the treatment of functional dyspepsia: a randomized double-blind, placebo-controlled trial. ( Amini, M; Babaei, M; Darvishi, A; Ghamar Chehreh, ME; Khedmat, H; Taheri, S; Valizadegan, G, 2012) |
| "The improvement in dysmotility-like dyspepsia symptom score on day 28 was significantly greater in the rabeprazole group (22." | 5.16 | Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia. ( Amemoto, K; Ashida, K; Esaki, H; Fukuchi, T; Hashimoto, T; Isowa, G; Kiyota, K; Majima, K; Morikawa, H; Murotani, M; Ohyama, Y; Oka, H; Sakaguchi, M; Takao, F; Takao, M; Yamashita, H, 2012) |
| "Camostat mesilate is superior to famotidine for relieving epigastralgia in patients with functional dyspepsia." | 5.12 | Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective? ( Ashizawa, N; Hashimoto, T; Imaoka, T; Kinoshita, Y; Miyake, T; Shizuku, T, 2006) |
| "007), indigestion and reflux syndrome after famotidine treatment." | 5.11 | Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. ( Asaka, M; Kato, M; Kitamori, S; Konishi, S; Konno, J; Kudo, M; Meguro, T; Nakagawa, S; Shimizu, Y; Takeda, H; Watanabe, M, 2005) |
| "Sixty-four functional dyspepsia patients without Helicobacter pylori infection were randomly assigned to 15 mg/day of mosapride, 40 mg/day of famotidine, or 30 mg/day of tandospirone during an 8-week treatment." | 5.11 | Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. ( Chiba, T; Nakase, H; Seno, H, 2005) |
| "To determine the benefit of using an H2-receptor antagonist in children with abdominal pain and dyspepsia, 25 such children were enrolled in a double-blind, placebo-controlled trial of famotidine." | 5.09 | Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. ( Benkov, KJ; Birnbaum, AH; Goldenberg, MM; Schechter, CB; See, MC, 2001) |
| "In a randomized, placebo-controlled, double-blind, crossover comparison, 12 patients with congestive heart failure (New York Heart Association class II) and dyspeptic complaints were treated orally for 1 week each with placebo, 40 mg omeprazole daily, and 40 mg famotidine daily." | 5.07 | Cardiovascular effects of omeprazole and famotidine. ( Halabi, A; Kirch, W, 1992) |
| "In this multicenter prospective single-arm open-label study, 10,311 patients with a clinical diagnosis of chronic symptomatic gastritis were enrolled and each patient was administered famotidine at 20 mg/day for 4 weeks." | 3.78 | Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study. ( Chiba, T; Kinoshita, Y, 2012) |
| " Adverse events (AEs) were collected beginning at the first dose and continued through completion (54 weeks)." | 2.80 | One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. ( Ball, J; Bello, AE; Grahn, AY; Holt, RJ; Kent, JD, 2015) |
| "Omeprazole can enhance efficacy of single and double antibiotic protocols and is particularly effective when combined with clarithromycin and a nitroimidazole." | 2.68 | Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. ( Andrews, P; Bae, H; Borody, TJ; Brandl, S; Fracchia, G; Shortis, NP, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hojo, M | 1 |
| Nagahara, A | 2 |
| Asaoka, D | 1 |
| Takeda, T | 1 |
| Izumi, K | 1 |
| Matsumoto, K | 2 |
| Ueyama, H | 1 |
| Shimada, Y | 1 |
| Nojiri, S | 1 |
| Watanabe, S | 2 |
| Bello, AE | 2 |
| Kent, JD | 2 |
| Grahn, AY | 2 |
| Ball, J | 2 |
| Holt, RJ | 2 |
| Taha, AS | 1 |
| Lazebnik, LB | 1 |
| Drozdov, VN | 1 |
| Kim, VA | 1 |
| Kinoshita, Y | 4 |
| Chiba, T | 2 |
| Amini, M | 1 |
| Ghamar Chehreh, ME | 1 |
| Khedmat, H | 1 |
| Valizadegan, G | 1 |
| Babaei, M | 1 |
| Darvishi, A | 1 |
| Taheri, S | 1 |
| Sakaguchi, M | 1 |
| Takao, M | 1 |
| Ohyama, Y | 1 |
| Oka, H | 1 |
| Yamashita, H | 1 |
| Fukuchi, T | 1 |
| Ashida, K | 1 |
| Murotani, M | 2 |
| Majima, K | 1 |
| Morikawa, H | 1 |
| Hashimoto, T | 3 |
| Kiyota, K | 1 |
| Esaki, H | 1 |
| Amemoto, K | 1 |
| Isowa, G | 1 |
| Takao, F | 1 |
| Sakurai, K | 1 |
| Inoue, K | 1 |
| Akiyama, J | 1 |
| Mabe, K | 1 |
| Suzuki, J | 1 |
| Habu, Y | 1 |
| Araki, A | 1 |
| Suzuki, T | 1 |
| Satoh, K | 1 |
| Nagami, H | 1 |
| Harada, R | 1 |
| Tano, N | 1 |
| Kusaka, M | 1 |
| Fujioka, Y | 1 |
| Fujimura, T | 1 |
| Shigeto, N | 1 |
| Oumi, T | 1 |
| Miwa, J | 1 |
| Miwa, H | 1 |
| Fujimoto, K | 1 |
| Haruma, K | 1 |
| Kato, M | 1 |
| Watanabe, M | 1 |
| Konishi, S | 1 |
| Kudo, M | 1 |
| Konno, J | 1 |
| Meguro, T | 1 |
| Kitamori, S | 1 |
| Nakagawa, S | 1 |
| Shimizu, Y | 1 |
| Takeda, H | 1 |
| Asaka, M | 1 |
| Seno, H | 1 |
| Nakase, H | 1 |
| Kawamura, A | 1 |
| Yuki, M | 1 |
| Amano, K | 1 |
| Sato, H | 1 |
| Adachi, K | 1 |
| Sato, S | 1 |
| Oshima, N | 1 |
| Takashima, T | 1 |
| Kitajima, N | 1 |
| Abe, K | 1 |
| Suetsugu, H | 1 |
| Otaka, M | 1 |
| Jin, M | 1 |
| Odashima, M | 1 |
| Matsuhashi, T | 1 |
| Wada, I | 1 |
| Horikawa, Y | 1 |
| Komatsu, K | 1 |
| Ohba, R | 1 |
| Oyake, J | 1 |
| Hatakeyama, N | 1 |
| Ashizawa, N | 1 |
| Miyake, T | 1 |
| Shizuku, T | 1 |
| Imaoka, T | 1 |
| Fukuda, M | 1 |
| Shirasaka, D | 1 |
| Aoyama, N | 1 |
| Miki, I | 1 |
| Kachi, M | 1 |
| Morita, Y | 1 |
| Tamura, T | 1 |
| Kasuga, M | 1 |
| Borody, TJ | 1 |
| Andrews, P | 1 |
| Fracchia, G | 1 |
| Brandl, S | 1 |
| Shortis, NP | 1 |
| Bae, H | 1 |
| Saha, N | 1 |
| Sachdev, A | 1 |
| Bhasin, DK | 1 |
| Sankaranahyanan, A | 1 |
| Khosla, PP | 1 |
| Singh, K | 1 |
| Sharma, PL | 1 |
| Netzer, P | 1 |
| Brabetz-Höfliger, A | 1 |
| Bründler, R | 1 |
| Flogerzi, B | 1 |
| Hüsler, J | 1 |
| Halter, F | 1 |
| See, MC | 1 |
| Birnbaum, AH | 1 |
| Schechter, CB | 1 |
| Goldenberg, MM | 1 |
| Benkov, KJ | 1 |
| Radwan, P | 1 |
| Grodzieński, R | 1 |
| Zaorska-Rajca, J | 1 |
| Skrzydło-Radomańska, B | 1 |
| Słomka, M | 1 |
| Wysokiński, A | 1 |
| Halabi, A | 1 |
| Kirch, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-Label Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-Steroidal Anti-Inflammatory Drug Treatment[NCT00984815] | Phase 3 | 86 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The non-pain symptom scale of the SODA questionnaire ranges from 7 - 35. Change from baseline compares the score at Week 54 to the baseline score for each participant that completed the non-pain symptom questions of the SODA questionnaire at baseline and Week 54. Higher scores indicate greater symptom severity and therefore a negative mean change from baseline is indicative of an improvement in symptoms. (NCT00984815)
Timeframe: Baseline and 54 Weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| HZT-501 | -1.44 |
The pain intensity scale of the SODA questionnaire ranges from 2 - 47. Change from baseline compares the score at Week 54 to the baseline score for each participant who completed the pain intensity questions of the SODA questionnaire at baseline and Week 54. Higher scores indicate greater symptom severity and therefore a negative mean change from baseline is indicative of an improvement in symptoms. (NCT00984815)
Timeframe: Baseline and 54 Weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| HZT-501 | -3.22 |
The satisfaction with dyspepsia-related health scale of the SODA questionnaire ranges from 2 - 23. Change from baseline compares the score at Week 54 to the baseline score for each participant who completed the Satisfaction questions of the SODA questionnaire at baseline and Week 54. A positive change from baseline in the SODA satisfaction scale represents a participant's overall improved satisfaction with their dyspepsia-related health. (NCT00984815)
Timeframe: Baseline and 54 Weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| HZT-501 | 2.69 |
(NCT00984815)
Timeframe: 54 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 76 |
19 trials available for famotidine and Dyspepsia
| Article | Year |
|---|---|
A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia.
Topics: Abdominal Pain; Adult; Benzamides; Cholinesterase Inhibitors; Double-Blind Method; Drug Synergism; D | 2017 |
One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Drug | 2015 |
One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Drug | 2015 |
[Efficiency of famotidin in prophylaxis of NSAIDs-induced gastropathy: result of multicenter research ZASLON-1 (protection of gastric mucosa from non-steroidal anti-inflammatory drugs].
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Dic | 2009 |
Famotidine in the treatment of functional dyspepsia: a randomized double-blind, placebo-controlled trial.
Topics: Double-Blind Method; Dyspepsia; Famotidine; Humans; Quality of Life; Treatment Outcome | 2012 |
Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzamides; Dyspepsia; Esop | 2012 |
Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS).
Topics: Algorithms; Benzamides; Diterpenes; Dose-Response Relationship, Drug; Dyspepsia; Famotidine; Gastroe | 2012 |
Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia.
Topics: Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Dyspepsia; Famotidine; Fema | 2005 |
Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzamides; Drug Therapy, Combination; Dyspepsia; Famotidine | 2005 |
Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia.
Topics: Anti-Anxiety Agents; Anti-Ulcer Agents; Benzamides; Dyspepsia; Famotidine; Female; Gastrointestinal | 2005 |
New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline.
Topics: Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Benzamides; Drug Therapy, Combination; Dyspep | 2005 |
Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective?
Topics: Anti-Ulcer Agents; Dyspepsia; Esters; Famotidine; Female; Gabexate; Guanidines; Humans; Japan; Male; | 2006 |
No significant difference in neutrophil activation found among three H2RAs.
Topics: Acetamides; Adult; Dyspepsia; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Hist | 2007 |
Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Famotidine; F | 1995 |
Clinical evaluation of the effect of omeprazole, cimetidine, famotidine and ranitidine on histamine induced cutaneous wheal and flare response.
Topics: Adult; Cimetidine; Drug Hypersensitivity; Dyspepsia; Famotidine; Female; Histamine; Histamine H2 Ant | 1993 |
Comparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidity.
Topics: Administration, Oral; Adult; Antacids; Calcium Carbonate; Carbonates; Double-Blind Method; Dyspepsia | 1998 |
Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment.
Topics: Abdominal Pain; Adolescent; Anti-Ulcer Agents; Breath Tests; Child; Child, Preschool; Double-Blind M | 2001 |
[The effect of prokinetic treatment and eradication of Helicobacter pylori on gastric emptying and symptoms of functional dyspepsia].
Topics: Adolescent; Adult; Cisapride; Drug Therapy, Combination; Dyspepsia; Famotidine; Female; Gastric Empt | 2001 |
Cardiovascular effects of omeprazole and famotidine.
Topics: Aged; Cardiac Output; Double-Blind Method; Dyspepsia; Famotidine; Female; Heart Failure; Hemodynamic | 1992 |
2 other studies available for famotidine and Dyspepsia
| Article | Year |
|---|---|
The ibuprofen-famotidine combined pill - a promise fulfilled.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dyspepsia; Famotidine; Female; Histamine H2 Antagonists; Hu | 2015 |
Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study.
Topics: Adult; Aged; Chronic Disease; Dyspepsia; Famotidine; Female; Gastritis; Heartburn; Histamine H2 Anta | 2012 |